MD1639C2 - ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei - Google Patents
ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a eiInfo
- Publication number
- MD1639C2 MD1639C2 MD94-0371A MD940371A MD1639C2 MD 1639 C2 MD1639 C2 MD 1639C2 MD 940371 A MD940371 A MD 940371A MD 1639 C2 MD1639 C2 MD 1639C2
- Authority
- MD
- Moldova
- Prior art keywords
- erythropoietin
- human
- fragments
- recombined
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Prezenta invenţie se referă la biotehnologie, industria medico-biologică, medicină şi în special, la ADN clonaţi, care codifică eritropoietina umană, expresiile ADN indicate şi la obţinerea in vitro a eritropoietinei umane active.Se descrie clonarea fragmentelor ADN genom din ficatul fetal uman şi fragmente ale ADNc, care asigură nivele excepţional de înalte ale expresiei eritropoietinei în celulele de mamifere, a fost obţinută linia de celule ovariene de hamster chinezesc CHO, care produce EPO recombinantă (CHO EPO Cla 4a4.02-7). Ca rezultat al expresiei fragmentelor clonate ale ADN în celulele de mamifere s-a obţinut EPO O-glicosilată cu o activitate specifică de cel puţin 200000 unităţi/mg şi compoziţia farmaceutică, în care se utilizează EPO recombinantă menţionată în calitate de ingredient activ.Rezultatul invenţiei constă în creşterea nivelelor de expresie in vitro a eritropoietinei umane active, precum şi în înlăturarea reacţiilor adverse în timpul tratamentului cu eritropoietină recombinantă umană.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67781384A | 1984-12-04 | 1984-12-04 | |
US68862285A | 1985-01-03 | 1985-01-03 | |
US69325885A | 1985-01-22 | 1985-01-22 | |
SU874203324A RU1801118C (ru) | 1985-01-22 | 1987-09-09 | Способ получени человеческого эритропоэтина |
Publications (3)
Publication Number | Publication Date |
---|---|
MD940371A MD940371A (ro) | 1996-06-28 |
MD1639B2 MD1639B2 (ro) | 2001-03-31 |
MD1639C2 true MD1639C2 (ro) | 2001-10-31 |
Family
ID=27418329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MD94-0371A MD1639C2 (ro) | 1984-12-04 | 1994-07-14 | ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei |
Country Status (24)
Country | Link |
---|---|
EP (2) | EP0205564B2 (ro) |
JP (4) | JPH02104284A (ro) |
KR (1) | KR890001011B1 (ro) |
AT (2) | ATE63137T1 (ro) |
AU (1) | AU621535B2 (ro) |
CA (1) | CA1341502C (ro) |
CZ (3) | CZ281756B6 (ro) |
DE (3) | DE3585161D1 (ro) |
DK (4) | DK172953B1 (ro) |
ES (1) | ES8800049A1 (ro) |
FI (2) | FI104261B (ro) |
GE (1) | GEP19970775B (ro) |
GR (1) | GR852890B (ro) |
HK (2) | HK105593A (ro) |
HU (1) | HU216079B (ro) |
IL (1) | IL77081A (ro) |
LV (2) | LV10505B (ro) |
MD (1) | MD1639C2 (ro) |
NO (1) | NO304469B1 (ro) |
PL (2) | PL157926B1 (ro) |
PT (1) | PT81590B (ro) |
SK (2) | SK168799A3 (ro) |
UA (1) | UA44882C2 (ro) |
WO (1) | WO1986003520A1 (ro) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
US4677195A (en) * | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
DE3789678T2 (de) * | 1986-02-27 | 1994-08-11 | Snow Brand Milk Prod Co Ltd | Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen. |
DK173067B1 (da) * | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
DK175363B1 (da) * | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5888774A (en) * | 1994-12-19 | 1999-03-30 | Cangene Corporation | Recombinant DNA molecules and expression vectors for erythropoietin |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
EP0752474A1 (en) | 1995-07-07 | 1997-01-08 | Boehringer Mannheim Gmbh | Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins |
EP0837942A1 (en) * | 1995-07-07 | 1998-04-29 | Boehringer Mannheim Gmbh | Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins |
DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
ATE222118T1 (de) | 1997-03-18 | 2002-08-15 | Roche Diagnostics Gmbh | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
PT986644E (pt) | 1997-07-23 | 2007-01-31 | Roche Diagnostics Gmbh | Preparação de eritropoietina por activação genética endógena com promotores virais |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
EP0986644B1 (de) * | 1997-07-23 | 2006-10-04 | Boehringer Mannheim GmbH | Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren |
DE59813913D1 (de) * | 1997-07-23 | 2007-04-05 | Roche Diagnostics Gmbh | Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung |
KR100622203B1 (ko) | 1997-07-23 | 2006-09-07 | 로셰 디아그노스틱스 게엠베하 | 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법 |
ES2208798T3 (es) * | 1997-09-01 | 2004-06-16 | Aventis Pharma Deutschland Gmbh | Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso. |
AR019025A1 (es) | 1998-04-09 | 2001-12-26 | Roche Diagnostics Gmbh | Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado |
BR9917606A (pt) | 1998-11-06 | 2002-12-31 | Bio Sidus S A | Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento |
US6777205B1 (en) | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
BR9905867A (pt) | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula |
BR9905868A (pt) | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
JP4656814B2 (ja) | 2000-12-20 | 2011-03-23 | エフ.ホフマン−ラ ロシュ アーゲー | エリスロポエチンコンジュゲート |
DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
KR100505152B1 (ko) * | 2001-09-10 | 2005-08-03 | (주)가이아진 | 아스코르브산을 이용한 에리트로포이에틴의 생산방법 |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
AU2002351444B2 (en) | 2001-12-07 | 2008-02-21 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
IL166506A0 (en) | 2002-09-11 | 2006-01-15 | Fresenius Kabi De Gmbh | Hasylated polypeptides especially hasylated erythropoietin |
ES2314238T3 (es) | 2002-10-08 | 2009-03-16 | Fresenius Kabi Deutschland Gmbh | Conjugados de oligosacaridos farmaceuticamente activos. |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
JP4865539B2 (ja) | 2003-05-09 | 2012-02-01 | クルセル ホランド ベー ヴェー | E1不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法 |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
ZA200603396B (en) | 2003-09-29 | 2007-11-28 | Warren Pharmaceuticals Inc | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
AU2004309083B2 (en) | 2003-12-30 | 2010-11-11 | Augustinus Bader | Tissue regeneration method |
DE102004004509B4 (de) | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
JP5396019B2 (ja) | 2004-03-11 | 2014-01-22 | フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート |
CN101659704A (zh) | 2004-03-11 | 2010-03-03 | 弗雷泽纽斯卡比德国有限公司 | 通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物 |
GB0507123D0 (en) * | 2005-04-08 | 2005-05-11 | Isis Innovation | Method |
EP1762250A1 (en) | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
CN101365719A (zh) | 2006-01-18 | 2009-02-11 | 中外制药株式会社 | 唾液酸的去除方法及去唾液酸***的制备方法 |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
EP1991569A4 (en) * | 2006-03-07 | 2009-12-23 | Regenetech Inc | MAMMALIAN BIOLOGICAL MOLECULES WITH NATURAL GLYCOSYLATION PRODUCED BY ELECTROMAGNETIC STIMULATION OF LIVING MAMMALIAN CELLS |
WO2007108505A1 (ja) | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
CN101534847A (zh) | 2006-08-04 | 2009-09-16 | 普罗龙药品公司 | 修饰型*** |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
EP2070950A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2095829A1 (en) | 2008-02-27 | 2009-09-02 | LEK Pharmaceuticals D.D. | Selenium containing modifying agents and conjugates |
DE102008002210A1 (de) | 2008-06-04 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur fermentativen Herstellung von Erythropoietin |
DE102008002209A1 (de) | 2008-06-04 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Aufreinigung von Erythropoietin |
WO2010034442A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
DE102008054716A1 (de) | 2008-12-16 | 2010-06-17 | Evonik Degussa Gmbh | Inprozesskontrolle in einem Verfahren zur Herstellung von EPO |
US20100272816A1 (en) | 2009-04-27 | 2010-10-28 | Wolfgang Rudinger | Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient |
AU2010297530B2 (en) | 2009-09-23 | 2013-12-19 | Ratiopharm Gmbh | Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same |
WO2017068051A1 (en) | 2015-10-21 | 2017-04-27 | Lek Pharmaceuticals D.D. | Peg-based dendron and process for producing the same |
CN106906359B (zh) | 2015-12-22 | 2018-12-11 | 理查德.亨威克 | 从硅酸盐矿物收取锂 |
WO2018172219A1 (en) | 2017-03-20 | 2018-09-27 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US439780A (en) * | 1890-11-04 | Method of and apparatus for casting ingots | ||
US3865801A (en) * | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
US4303650A (en) * | 1979-10-09 | 1981-12-01 | Ajinomoto Co., Inc. | Process for production of erythropoietin |
US4377513A (en) * | 1980-08-25 | 1983-03-22 | Ken Hayashibara | Process for the production of human erythropoietin |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5455790A (en) * | 1977-10-05 | 1979-05-04 | Tomoyuki Tajima | Production of erythropoetin |
US4419446A (en) * | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
JPS6043395A (ja) * | 1983-08-19 | 1985-03-07 | Sumitomo Chem Co Ltd | エリスロポエチンの製造法 |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
IT1185503B (it) * | 1984-01-11 | 1987-11-12 | Univ New York | Cloni di odna di eritropietina umana |
JPS60215632A (ja) * | 1984-04-12 | 1985-10-29 | Japan Found Cancer | エリスロポエチンの製造法 |
US4732889A (en) * | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
JPH062070B2 (ja) * | 1988-07-06 | 1994-01-12 | 農林水産省食品総合研究所長 | ▲o下−▼アシルアミノ酸の製造方法 |
-
1985
- 1985-11-18 IL IL7708185A patent/IL77081A/en not_active IP Right Cessation
- 1985-12-02 PT PT81590A patent/PT81590B/pt unknown
- 1985-12-02 GR GR852890A patent/GR852890B/el unknown
- 1985-12-03 PL PL1985287787A patent/PL157926B1/pl unknown
- 1985-12-03 AT AT86900439T patent/ATE63137T1/de not_active IP Right Cessation
- 1985-12-03 CA CA000496740A patent/CA1341502C/en not_active Expired - Fee Related
- 1985-12-03 EP EP86900439A patent/EP0205564B2/en not_active Expired - Lifetime
- 1985-12-03 DE DE9090118215T patent/DE3585161D1/de not_active Expired - Lifetime
- 1985-12-03 DE DE8686900439T patent/DE3582732D1/de not_active Expired - Lifetime
- 1985-12-03 AU AU53134/86A patent/AU621535B2/en not_active Withdrawn - After Issue
- 1985-12-03 ES ES549539A patent/ES8800049A1/es not_active Expired
- 1985-12-03 GE GEAP19851901A patent/GEP19970775B/en unknown
- 1985-12-03 PL PL1985256589A patent/PL154180B1/pl unknown
- 1985-12-03 EP EP90118215A patent/EP0411678B2/en not_active Expired - Lifetime
- 1985-12-03 SK SK1687-99A patent/SK168799A3/sk unknown
- 1985-12-03 AT AT90118215T patent/ATE71408T1/de not_active IP Right Cessation
- 1985-12-03 DE DE199090118215T patent/DE411678T1/de active Pending
- 1985-12-03 HU HU553/86A patent/HU216079B/hu unknown
- 1985-12-03 SK SK8804-85A patent/SK279765B6/sk unknown
- 1985-12-03 CZ CS858804A patent/CZ281756B6/cs not_active IP Right Cessation
- 1985-12-03 WO PCT/US1985/002405 patent/WO1986003520A1/en active IP Right Grant
-
1986
- 1986-07-24 FI FI863044A patent/FI104261B/fi not_active IP Right Cessation
- 1986-07-28 NO NO863050A patent/NO304469B1/no not_active IP Right Cessation
- 1986-08-01 DK DK198603687A patent/DK172953B1/da not_active IP Right Cessation
- 1986-08-04 KR KR8670525A patent/KR890001011B1/ko not_active IP Right Cessation
-
1988
- 1988-03-18 JP JP63065592A patent/JPH02104284A/ja active Pending
- 1988-03-18 JP JP63065591A patent/JPH0655144B2/ja not_active Expired - Lifetime
- 1988-08-09 JP JP63198766A patent/JPH02442A/ja active Pending
-
1991
- 1991-11-15 UA UA5010104A patent/UA44882C2/uk unknown
-
1992
- 1992-12-02 JP JP4323466A patent/JPH07184681A/ja active Pending
-
1993
- 1993-06-08 LV LVP-93-500A patent/LV10505B/lv unknown
- 1993-06-10 LV LVP-93-623A patent/LV10507B/lv unknown
- 1993-10-07 HK HK1055/93A patent/HK105593A/xx not_active IP Right Cessation
- 1993-10-07 HK HK1056/93A patent/HK105693A/xx not_active IP Right Cessation
-
1994
- 1994-07-14 MD MD94-0371A patent/MD1639C2/ro not_active IP Right Cessation
-
1996
- 1996-05-02 CZ CZ19961274A patent/CZ286557B6/cs not_active IP Right Cessation
-
1997
- 1997-08-20 DK DK95197A patent/DK173254B1/da not_active IP Right Cessation
-
1999
- 1999-08-20 DK DK199901147A patent/DK173293B1/da not_active IP Right Cessation
- 1999-09-27 FI FI992064A patent/FI105347B/fi not_active IP Right Cessation
- 1999-12-02 CZ CZ19994314A patent/CZ287620B6/cs not_active IP Right Cessation
-
2000
- 2000-03-29 DK DK200000527A patent/DK175826B1/da not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US439780A (en) * | 1890-11-04 | Method of and apparatus for casting ingots | ||
US3865801A (en) * | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
US4303650A (en) * | 1979-10-09 | 1981-12-01 | Ajinomoto Co., Inc. | Process for production of erythropoietin |
US4377513A (en) * | 1980-08-25 | 1983-03-22 | Ken Hayashibara | Process for the production of human erythropoietin |
Non-Patent Citations (8)
Title |
---|
Alan R. Liss, Inc. New York (1980 * |
Carnot et al., Compt. Rend. 143:384, 1966; * |
Espada et al., Biochem. Med., 3:475, 1970; * |
Fischer, Pharm. Rev., 24:459, 1972; * |
Goldwasser, Control Cellular, Dif. Develop. Part. A, p. 487-494; * |
Gordon, Vitam. Horm. (N.Y.), 31:105, 1973; * |
Guyton, Textbook of medical Phisiology, W. B. Saunders Co, Filadelfia, p. 56 -60, 1976; * |
White et al., Rec. Progr. Horm. Res., 16-219, 1960; * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD1639C2 (ro) | ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei | |
DE211894T1 (de) | Fsh. | |
FR2681786B1 (ro) | ||
DE69133459D1 (de) | Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen | |
IT1206311B (it) | Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso. | |
ES8401777A1 (es) | Procedimiento para producir un polipeptido. | |
IL200005A (en) | METHOD FOR THE PRODUCTION OF ALPH 2, 6 - GALACTOSIDES AND HUMAN CYLILE EXTRACTED | |
BR9712348A (pt) | molécula de polinucleotídeo isolada, vetor de expressão, célula cultivada em que foi introduzido um vetor de expressão, processo para produzir um polipeptídeo homólogo de fgf, polipeptídeo homólogo de fgf isolado,composição farmacêutica, anticorpo, processos para estimular ex vivo células progenitoras de miócitos, e, paraliberar um agente ou droga seletivamente para o tecido do coração. | |
FR2564097B1 (fr) | Polypeptide physiologiquement actif humain, acide desoxyribonucleique comprenant une sequence de base codant ce polypeptide, procede de production de ce polypeptide, et composition pharmaceutique le contenant | |
KR880700071A (ko) | 다능성 과립구 군체-자극 인자의 생산 | |
IL74947A (en) | Analogs of human gamma interferon having the partial sequence of human gamma interferon and genetic engineering process for the preparation thereof | |
HU903961D0 (en) | Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds | |
HUT56884A (en) | Process for producing protein having urate oxidase activity, gene coding for it, expression vector, microorganisms and transformed cells | |
EP0232523A3 (en) | Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins | |
KR920004570A (ko) | 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법 | |
IL88034A0 (en) | Mutant acidic fibroblast growth factor,its preparation and pharmaceutical compositions containing it | |
ATE139568T1 (de) | Achromobacter-protease-i-gen sowie genprodukt | |
EP0218652B1 (en) | A dna sequence | |
HUP9800520A2 (hu) | Génexpresszió emlős sejtekben | |
EP0516845A4 (en) | NEW MEGAKARYOCYTIC COLONY-STIMULATING FACTOR AND METHOD FOR THE PRODUCTION THEREOF. | |
DE3567213D1 (en) | Erythromycin a salt with mucosecretolytic and fluidizing activity, a process for its preparation and pharmaceutical compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD99 | Pending application | ||
KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
MK4A | Patent for invention expired |